Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ: TELO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Erez Aminov
- Employees
- 1
- Headquarters
- Baltimore, United States
- IPO year
- 2019
- Market cap
- $42.3M
- Website
- https://telomirpharma.com
Loading TELO…
Loading profile data…Frequently asked questions about TELO
What does Telomir Pharmaceuticals, Inc. Common Stock (TELO) do?
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against...
Where does TELO trade?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) trades on the NASDAQ Capital Market.
What sector is TELO in?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Telomir Pharmaceuticals, Inc. Common Stock?
Erez Aminov is the chief executive officer of Telomir Pharmaceuticals, Inc. Common Stock (TELO).
Where is Telomir Pharmaceuticals, Inc. Common Stock headquartered?
Telomir Pharmaceuticals, Inc. Common Stock is headquartered in United States.
Does TELO pay a dividend?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TELO go public?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) completed its initial public offering in 2019.